| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8536983 | Pharmacology & Therapeutics | 2018 | 53 Pages |
Abstract
Despite promising evidence, widespread clinical application of both EPCs and CPCs remains delayed due to several unresolved issues. The present review provides a summary of the different applications of EPCs and CPCs for cardiovascular cell therapy and underlies their advantages and limitations.
Keywords
STEMIDil-Ac-LDLUlex europaeus agglutinin-1SSEA-1UEA-1Sca-1ISL-1ECFCsTβ4PDGFRBMCsCPCIPDEPCsCXCR4IPSCsEPCCPCSSDF-1Stem Cell Antigen-1Myocardial infarctionST-segment elevation myocardial infarctionLeft ventricularThymosin β4Side populationindividual patient dataStem cellsInduced pluripotent stem cellsbone marrow-derived cellsCardiac progenitor cellsEndothelial progenitor cellsEndothelial colony forming cellsStromal cell derived factor-1granulocyte colony-stimulating factorVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)G-CSFcardiovascularbone marrowSkeletal myoblastsC-X-C chemokine receptor type 4Regenerative medicineplatelet-derived growth factor receptor
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Vanessa Bianconi, Amirhossein Sahebkar, Petri Kovanen, Francesco Bagaglia, Biagio Ricciuti, Paolo Calabrò, Giuseppe Patti, Matteo Pirro,